{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T18:40:50Z","timestamp":1788720050362,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005192","name":"California HIV\/AIDS Research Program","doi-asserted-by":"publisher","award":["EI11-SD-005B"],"award-info":[{"award-number":["EI11-SD-005B"]}],"id":[{"id":"10.13039\/100005192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005192","name":"California HIV\/AIDS Research Program","doi-asserted-by":"publisher","award":["EI11-SD-005B"],"award-info":[{"award-number":["EI11-SD-005B"]}],"id":[{"id":"10.13039\/100005192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005192","name":"California HIV\/AIDS Research Program","doi-asserted-by":"publisher","award":["EI11-SD-005B"],"award-info":[{"award-number":["EI11-SD-005B"]}],"id":[{"id":"10.13039\/100005192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005192","name":"California HIV\/AIDS Research Program","doi-asserted-by":"publisher","award":["EI11-SD-005B"],"award-info":[{"award-number":["EI11-SD-005B"]}],"id":[{"id":"10.13039\/100005192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005192","name":"California HIV\/AIDS Research Program","doi-asserted-by":"publisher","award":["EI11-SD-005B"],"award-info":[{"award-number":["EI11-SD-005B"]}],"id":[{"id":"10.13039\/100005192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005192","name":"California HIV\/AIDS Research Program","doi-asserted-by":"publisher","award":["EI11-SD-005B"],"award-info":[{"award-number":["EI11-SD-005B"]}],"id":[{"id":"10.13039\/100005192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005192","name":"California HIV\/AIDS Research Program","doi-asserted-by":"publisher","award":["EI11-SD-005B"],"award-info":[{"award-number":["EI11-SD-005B"]}],"id":[{"id":"10.13039\/100005192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005192","name":"California HIV\/AIDS Research Program","doi-asserted-by":"publisher","award":["EI11-SD-005B"],"award-info":[{"award-number":["EI11-SD-005B"]}],"id":[{"id":"10.13039\/100005192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["KL2TR001444"],"award-info":[{"award-number":["KL2TR001444"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008673","name":"Center for AIDS Research, University of California, San Diego","doi-asserted-by":"publisher","award":["P30AI036214"],"award-info":[{"award-number":["P30AI036214"]}],"id":[{"id":"10.13039\/100008673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008673","name":"Center for AIDS Research, University of California, San Diego","doi-asserted-by":"publisher","award":["P30AI036214"],"award-info":[{"award-number":["P30AI036214"]}],"id":[{"id":"10.13039\/100008673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008673","name":"Center for AIDS Research, University of California, San Diego","doi-asserted-by":"publisher","award":["P30AI036214"],"award-info":[{"award-number":["P30AI036214"]}],"id":[{"id":"10.13039\/100008673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008673","name":"Center for AIDS Research, University of California, San Diego","doi-asserted-by":"publisher","award":["P30AI036214"],"award-info":[{"award-number":["P30AI036214"]}],"id":[{"id":"10.13039\/100008673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008673","name":"Center for AIDS Research, University of California, San Diego","doi-asserted-by":"publisher","award":["P30AI036214"],"award-info":[{"award-number":["P30AI036214"]}],"id":[{"id":"10.13039\/100008673","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cisgender women account for 1 in 5 new HIV infections in the United States, yet remain under-engaged in HIV prevention. Women experiencing violence face risk for HIV due to biological and behavioral mechanisms, and barriers to prevention, such as challenges to Pre-Exposure Prophylaxis for HIV Prevention (PrEP) adherence. In this analysis, we aim to characterize intimate partner violence (IPV) among cisgender heterosexual women enrolled in a PrEP demonstration project and assess the associations with PrEP adherence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Adherence Enhancement Guided by Individualized Texting and Drug Levels (AEGiS) was a 48-week single-arm open-label study of PrEP adherence in HIV-negative cisgender women in Southern California (<jats:italic>N<\/jats:italic>\u2009=\u2009130) offered daily tenofovir disoproxil fumarate\/emtricitabine (TDF\/FTC). From 6\/2016 to 10\/2018, women completed a survey reporting HIV risk behavior and experiences of any IPV (past 90-days) and IPV sub-types (past-year, lifetime) and biological testing for HIV\/STIs at baseline, and concentrations of tenofovir-diphosphate (TFV-DP) in dried blood spots at weeks 4, 12, 24, 36, and 48. Outcomes were TFV-DP concentrations consistent with \u2265\u20094 or \u2265\u20096 doses\/week at one or multiple visits. Multivariable logistic regression models were conducted to examine associations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Past-90-day IPV was reported by 34.4% of participants, and past-year and lifetime subtypes reported by 11.5-41.5%, and 21.5-52.3%, respectively. Women who engaged in sex work and Black women were significantly more likely to report IPV than others. Lifetime physical IPV was negatively associated with adherence at \u2265\u20094 doses\/week at \u2265\u20093 of 5 visits, while other relationships with any IPV and IPV sub-types were variable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>IPV is an indication for PrEP and important indicator of HIV risk; our findings suggest that physical IPV may also negatively impact long-term PrEP adherence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical Trials Registration<\/jats:title>\n                <jats:p>NCT02584140 (ClinicalTrials.gov), registered 15\/10\/2015.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-024-18946-4","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T10:03:43Z","timestamp":1717149823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The impact of intimate partner violence on PrEP adherence among U.S. Cisgender women at risk for HIV"],"prefix":"10.1186","volume":"24","author":[{"given":"Katherine M.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Rivet","family":"Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Landovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Zachek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila K.","family":"Stockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"18946_CR1","unstructured":"Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010\u20132016. 2019."},{"issue":"11","key":"18946_CR2","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1007\/s10461-019-02494-9","volume":"23","author":"A Geter","year":"2019","unstructured":"Geter A, Sutton MY, Armon C, Buchacz K. Disparities in viral suppression and medication adherence among women in the USA, 2011\u20132016. AIDS Behav. 2019;23(11):3015\u201323.","journal-title":"AIDS Behav"},{"key":"18946_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2147\/IJWH.S113675","volume":"9","author":"CA Flash","year":"2017","unstructured":"Flash CA, Dale SK, Krakower DS. Pre-exposure prophylaxis for HIV prevention in women: current perspectives. Int J Womens Health. 2017;9:391\u2013401.","journal-title":"Int J Womens Health"},{"issue":"2","key":"18946_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/09540121.2020.1762067","volume":"33","author":"TC Willie","year":"2021","unstructured":"Willie TC, Kershaw TS, Blackstock O, Galvao RW, Safon CB, Tekeste M, et al. Racial and ethnic differences in women\u2019s HIV risk and attitudes towards pre-exposure prophylaxis (PrEP) in the context of the substance use, violence, and depression syndemic. AIDS Care. 2021;33(2):219\u201328.","journal-title":"AIDS Care"},{"issue":"1","key":"18946_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/sextrans-2021-055224","volume":"99","author":"K Tsuyuki","year":"2023","unstructured":"Tsuyuki K, Chan E, Lucea MB, Cimino A, Rudolph AE, Tesfai Y, et al. Characterising a syndemic among black women at risk for HIV: the role of sociostructural inequity and adverse childhood experiences. Sex Transm Infect. 2023;99(1):7\u201313.","journal-title":"Sex Transm Infect"},{"issue":"5","key":"18946_CR6","doi-asserted-by":"publisher","first-page":"e0252338","DOI":"10.1371\/journal.pone.0252338","volume":"16","author":"AM Leddy","year":"2021","unstructured":"Leddy AM, Zakaras JM, Shieh J, Conroy AA, Ofotokun I, Tien PC, Weiser SD. Intersections of food insecurity, violence, poor mental health and substance use among US women living with and at risk for HIV: evidence of a syndemic in need of attention. PLoS ONE. 2021;16(5):e0252338.","journal-title":"PLoS ONE"},{"issue":"10","key":"18946_CR7","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.2105\/AJPH.2014.302430","volume":"105","author":"BEE Montgomery","year":"2015","unstructured":"Montgomery BEE, Rompalo A, Hughes J, Wang J, Haley D, Soto-Torres L, et al. Violence against women in selected areas of the United States. Am J Public Health. 2015;105(10):2156\u201366.","journal-title":"Am J Public Health"},{"key":"18946_CR8","unstructured":"Leemis RW, Friar N, Khatiwada S, Chen MS, Kresnow M-j, Smith SG et al. The National Intimate Partner and Sexual Violence Survey: 2016\/2017 Report on Intimate Partner Violence. 2022."},{"issue":"5","key":"18946_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/archpedi.162.5.432","volume":"162","author":"JM Sales","year":"2008","unstructured":"Sales JM, Salazar LF, Wingood GM, DiClemente RJ, Rose E, Crosby RA. The mediating role of partner communication skills on HIV\/STD\u2013associated risk behaviors in young African American females with a history of sexual violence. Arch Pediatr Adolesc Med. 2008;162(5):432\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"18946_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1300\/J070v13n01_01","volume":"13","author":"SC Kalichman","year":"2004","unstructured":"Kalichman SC, Gore-Felton C, Benotsch E, Cage M, Rompa D. Trauma symptoms, sexual behaviors, and substance abuse: correlates of childhood sexual abuse and HIV risks among men who have sex with men. J Child Sex Abuse. 2004;13(1):1\u201315.","journal-title":"J Child Sex Abuse"},{"issue":"6","key":"18946_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1089\/apc.2016.0098","volume":"30","author":"A Braksmajer","year":"2016","unstructured":"Braksmajer A, Senn TE, McMahon J. The potential of Pre-exposure Prophylaxis for women in Violent relationships. AIDS Patient Care STDs. 2016;30(6):274\u201381.","journal-title":"AIDS Patient Care STDs"},{"issue":"2","key":"18946_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/0886260511416469","volume":"27","author":"H Cho","year":"2011","unstructured":"Cho H. Racial differences in the Prevalence of Intimate Partner Violence Against Women and Associated Factors. J Interpers Violence. 2011;27(2):344\u201363.","journal-title":"J Interpers Violence"},{"issue":"1","key":"18946_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1077801204271476","volume":"11","author":"NJ Sokoloff","year":"2005","unstructured":"Sokoloff NJ, Dupont I. Domestic violence at the intersections of race, class, and gender: challenges and contributions to understanding violence against marginalized women in diverse communities. Violence against Women. 2005;11(1):38\u201364.","journal-title":"Violence against Women"},{"issue":"5","key":"18946_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/YCO.0000000000000182","volume":"28","author":"VA Satyanarayana","year":"2015","unstructured":"Satyanarayana VA, Chandra PS, Vaddiparti K. Mental health consequences of violence against women and girls. Curr Opin Psychiatry. 2015;28(5):350\u20136.","journal-title":"Curr Opin Psychiatry"},{"issue":"8","key":"18946_CR15","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1089\/jwh.2018.7597","volume":"28","author":"J Zhou","year":"2019","unstructured":"Zhou J, Ko JY, Haight SC, Tong VT. Treatment of Substance Use disorders among women of Reproductive Age by Depression and anxiety disorder status, 2008\u20132014. J Womens Health (Larchmt). 2019;28(8):1068\u201376.","journal-title":"J Womens Health (Larchmt)"},{"issue":"7256","key":"18946_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/bmj.321.7256.263","volume":"321","author":"S Ramrakha","year":"2000","unstructured":"Ramrakha S, Caspi A, Dickson N, Moffitt TE, Paul C. Psychiatric disorders and risky sexual behaviour in young adulthood: cross sectional study in birth cohort. BMJ. 2000;321(7256):263\u20136.","journal-title":"BMJ"},{"issue":"3","key":"18946_CR17","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s10461-012-0361-4","volume":"17","author":"JK Stockman","year":"2013","unstructured":"Stockman JK, Lucea MB, Campbell JC. Forced sexual initiation, sexual intimate partner violence and HIV risk in women: a global review of the literature. AIDS Behav. 2013;17(3):832\u201347.","journal-title":"AIDS Behav"},{"issue":"Suppl 1","key":"18946_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/aji.12027","volume":"69","author":"M Ghosh","year":"2013","unstructured":"Ghosh M, Rodriguez-Garcia M, Wira CR. Immunobiology of genital tract trauma: endocrine regulation of HIV acquisition in women following sexual assault or genital tract mutilation. Am J Reprod Immunol. 2013;69(Suppl 1):51\u201360.","journal-title":"Am J Reprod Immunol"},{"issue":"1","key":"18946_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1089\/apc.2017.0201","volume":"32","author":"E Aaron","year":"2018","unstructured":"Aaron E, Blum C, Seidman D, Hoyt MJ, Simone J, Sullivan M, Smith DK. Optimizing delivery of HIV Preexposure Prophylaxis for women in the United States. AIDS Patient Care STDS. 2018;32(1):16\u201323.","journal-title":"AIDS Patient Care STDS"},{"key":"18946_CR20","doi-asserted-by":"crossref","unstructured":"Murnane PM, Celum C, Nelly M, Campbell JD, Donnell D, Bukusi E et al. Efficacy of pre-exposure prophylaxis for HIV-1 prevention among high risk heterosexuals: subgroup analyses from the Partners PrEP Study. AIDS (London, England). 2013;27(13).","DOI":"10.1097\/QAD.0b013e3283629037"},{"issue":"5","key":"18946_CR21","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1007\/s10461-019-02743-x","volume":"24","author":"TL O\u2019Malley","year":"2020","unstructured":"O\u2019Malley TL, Hawk ME, Egan JE, Krier SE, Burke JG. Intimate Partner Violence and Pre-exposure Prophylaxis (PrEP): a Rapid Review of current evidence for women\u2019s HIV Prevention. AIDS Behav. 2020;24(5):1342\u201357.","journal-title":"AIDS Behav"},{"issue":"12","key":"18946_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.annepidem.2018.05.003","volume":"28","author":"DK Smith","year":"2018","unstructured":"Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race\/ethnicity, United States, 2015. Ann Epidemiol. 2018;28(12):850\u2013e79.","journal-title":"Ann Epidemiol"},{"issue":"9","key":"18946_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/01.NPR.0000855308.51321.39","volume":"47","author":"JJ Mayeux","year":"2022","unstructured":"Mayeux JJ, Ng YC. Preexposure prophylaxis for HIV prevention: a highlight of the updated clinical practice guideline. The Nurse Practitioner. 2022;47(9):44\u20137.","journal-title":"The Nurse Practitioner"},{"key":"18946_CR24","unstructured":"AIDSVu. Emory University, Rollins School of Public Health.; [Available from: aidsvu.org]."},{"issue":"41","key":"18946_CR25","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.15585\/mmwr.mm6741a3","volume":"67","author":"AH Ya-lin","year":"2018","unstructured":"Ya-lin AH, Zhu W, Smith DK, Harris N, Hoover KW. HIV preexposure prophylaxis, by race and ethnicity\u2014United States, 2014\u20132016. Morb Mortal Wkly Rep. 2018;67(41):1147.","journal-title":"Morb Mortal Wkly Rep"},{"key":"18946_CR26","doi-asserted-by":"crossref","unstructured":"Bradley E, Forsberg K, Betts JE, DeLuca JB, Kamitani E, Porter SE et al. Factors Affecting Pre-Exposure Prophylaxis Implementation for Women in the United States: A Systematic Review. Journal of women\u2019s health (2002). 2019;28(9):1272-85.","DOI":"10.1089\/jwh.2018.7353"},{"issue":"2","key":"18946_CR27","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s10461-019-02469-w","volume":"24","author":"TC Willie","year":"2020","unstructured":"Willie TC, Keene DE, Stockman JK, Alexander KA, Calabrese SK, Kershaw TS. Intimate Partner Violence influences women\u2019s Engagement in the early stages of the HIV pre-exposure Prophylaxis (PrEP) care continuum: using doubly robust estimation. AIDS Behav. 2020;24(2):560\u20137.","journal-title":"AIDS Behav"},{"issue":"7","key":"18946_CR28","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1080\/09540121.2017.1286287","volume":"29","author":"OJ Blackstock","year":"2017","unstructured":"Blackstock OJ, Patel VV, Felsen U, Park C, Jain S. Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinic. AIDS Care. 2017;29(7):866\u20139.","journal-title":"AIDS Care"},{"issue":"5","key":"18946_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/QAI.0000000000001129","volume":"73","author":"JL Marcus","year":"2016","unstructured":"Marcus JL, Hurley LB, Hare CB, Nguyen DP, Phengrasamy T, Silverberg MJ, et al. Preexposure Prophylaxis for HIV Prevention in a large Integrated Health Care System: adherence, Renal Safety, and discontinuation. J Acquir Immune Defic Syndr. 2016;73(5):540\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"18946_CR30","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1186\/s12879-021-06786-1","volume":"21","author":"TC Willie","year":"2021","unstructured":"Willie TC, Monger M, Nunn A, Kershaw T, Stockman JK, Mayer KH, et al. PrEP\u2019s just to secure you like insurance: a qualitative study on HIV pre-exposure prophylaxis (PrEP) adherence and retention among black cisgender women in Mississippi. BMC Infect Dis. 2021;21(1):1102.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"18946_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/QAI.0000000000002956","volume":"90","author":"L Sharpless","year":"2022","unstructured":"Sharpless L, Kershaw T, Hatcher A, Alexander KA, Katague M, Phillips K, Willie TC. IPV, PrEP, and Medical Mistrust. J Acquir Immune Defic Syndr. 2022;90(3):283\u201390.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"18946_CR32","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1007\/s10461-021-03565-6","volume":"26","author":"NK Jeffers","year":"2022","unstructured":"Jeffers NK, Zemlak JL, Celius L, Willie TC, Kershaw T, Alexander KA. If the Partner finds out, then there\u2019s trouble\u2019: provider perspectives on Safety Planning and Partner Interference when Offering HIV pre-exposure Prophylaxis (PrEP) to women experiencing intimate Partner Violence (IPV). AIDS Behav. 2022;26(7):2266\u201378.","journal-title":"AIDS Behav"},{"issue":"2","key":"18946_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/QAI.0000000000001574","volume":"77","author":"A Cabral","year":"2018","unstructured":"Cabral A, Baeten M, Ngure J, Velloza K, Odoyo J, Haberer JE. Intimate Partner Violence and Self-reported pre-exposure Prophylaxis interruptions among HIV-Negative partners in HIV serodiscordant couples in Kenya and Uganda. J Acquir Immune Defic Syndr. 2018;77(2):154\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"18946_CR34","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/cid\/ciab328","volume":"73","author":"J Blumenthal","year":"2021","unstructured":"Blumenthal J, Jain S, He F, Amico KR, Kofron R, Ellorin E, et al. Results from a pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender women in the United States. Clin Infect Dis. 2021;73(7):1149\u201356.","journal-title":"Clin Infect Dis"},{"key":"18946_CR35","volume-title":"Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142014: a clinical practice guideline","author":"US Public Health Service","year":"2014","unstructured":"US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142014: a clinical practice guideline. Washington, DC: US Public Health Service; 2014."},{"issue":"2","key":"18946_CR36","first-page":"317","volume":"61","author":"RR Newton","year":"2001","unstructured":"Newton RR, Connelly CD, Landsverk JA. An examination of measurement characteristics and factorial validity of the revised conflict tactics Scale. Educ Psychol Meas. 2001;61(2):317\u201335.","journal-title":"Educ Psychol Meas"},{"key":"18946_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jpba.2016.01.038","volume":"122","author":"JH Zheng","year":"2016","unstructured":"Zheng JH, Rower C, McAllister K, Castillo-Mancilla J, Klein B, Meditz A, et al. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal. 2016;122:16\u201320.","journal-title":"J Pharm Biomed Anal"},{"key":"18946_CR38","doi-asserted-by":"crossref","unstructured":"Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018;62(1).","DOI":"10.1128\/AAC.01710-17"},{"issue":"9","key":"18946_CR39","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3109\/01612840.2015.1025319","volume":"36","author":"E Reeves","year":"2015","unstructured":"Reeves E. A synthesis of the literature on trauma-informed care. Issues Ment Health Nurs. 2015;36(9):698\u2013709.","journal-title":"Issues Ment Health Nurs"},{"issue":"4","key":"18946_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11904-021-00555-0","volume":"18","author":"JM Sales","year":"2021","unstructured":"Sales JM, Anderson KM, Kokubun CW. Application of the Consolidated Framework for Implementation Research to facilitate violence screening in HIV Care settings: a review of the literature. Curr HIV\/AIDS Rep. 2021;18(4):309\u201327.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"10","key":"18946_CR41","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1176\/appi.ps.56.10.1213","volume":"56","author":"JP Morrissey","year":"2005","unstructured":"Morrissey JP, Jackson EW, Ellis AR, Amaro H, Brown VB, Najavits LM. Twelve-month outcomes of trauma-informed interventions for women with co-occurring disorders. Psychiatric Serv. 2005;56(10):1213\u201322.","journal-title":"Psychiatric Serv"},{"key":"18946_CR42","unstructured":"Substance Abuse and Mental Health Services Administration. Trauma-Informed Care in Behavioral Health Services. Rockville, MD: Substance Abuse and Mental Health Services Administration. 2014. Contract No.: HHS Publication No. (SMA) 13-4801."},{"issue":"5","key":"18946_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.whi.2021.05.003","volume":"31","author":"TC Willie","year":"2021","unstructured":"Willie TC, Alexander KA, Kershaw T, Campbell JC, Stockman JK. No longer the exception, but the Standard: integrating trauma-informed policy and pre-exposure prophylaxis implementation for women. Womens Health Issues. 2021;31(5):415\u20139.","journal-title":"Womens Health Issues"},{"issue":"2","key":"18946_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.psym.2014.10.006","volume":"56","author":"C Brezing","year":"2015","unstructured":"Brezing C, Ferrara M, Freudenreich O. The Syndemic illness of HIV and Trauma: implications for a trauma-informed model of Care. Psychosomatics. 2015;56(2):107\u201318.","journal-title":"Psychosomatics"},{"issue":"6","key":"18946_CR45","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s11904-016-0337-5","volume":"13","author":"JM Sales","year":"2016","unstructured":"Sales JM, Swartzendruber A, Phillips AL. Trauma-informed HIV, Prevention and Treatment. Curr HIV\/AIDS Rep. 2016;13(6):374\u201382.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"18946_CR46","unstructured":"FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. [press release]. U.S. Food and Drug Administration2021."},{"issue":"6","key":"18946_CR47","doi-asserted-by":"publisher","first-page":"e1003670","DOI":"10.1371\/journal.pmed.1003670","volume":"18","author":"C Celum","year":"2021","unstructured":"Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6):e1003670.","journal-title":"PLoS Med"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18946-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-18946-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18946-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T10:04:58Z","timestamp":1717149898000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-18946-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["18946"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-18946-4","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"assertion":[{"value":"31 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol was approved by the relevant Institutional Review Boards at University of California Los Angeles, Harbor-UCLA Medical Center, University of Southern California, and University of California San Diego. The study was registered at clinicaltrials.gov (NCT02584140) on 15\/10\/2015. All participants provided informed consent prior to study screening.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KMA, SJ, XS, KRA, CZ, DM, and JKS have no competing interests to declare. JB reports research funding from Gilead Sciences outside of the submitted work. RL reports personal fees from Gilead Sciences and personal fees from Merck, outside the submitted work. SM reports research funding form Gilead Sciences and Merck, stock in Bristol Myers Squibb and Pfizer, and is a cofounder of Aspera Biomedicines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1461"}}